Magnetic resonance imaging-radiomics evaluation of response to chemotherapy for synchronous liver metastasis of colorectal cancer

Table 1 Baseline patient characteristics

General characteristics	non-DR, n = 53	DR, n = 49	P value
Demographics
Gender (female/male)	28/25	17/32	0.065
Age (mean ± SD)	63.3 ± 11.1/63.2 ± 7.5	58.6 ± 11.2/59.7 ± 14.1	0.117
Tumor markers
AFP (normal/abnormal)	51/2	47/2	0.936
CEA (normal/abnormal)	14/39	14/35	0.807
CA19-9 (normal/abnormal)	30/23	18/31	0.045
Clinical T/N staging
T1/T2/T3/T4	0/1/48/4	0/10/33/6	0.136
N0/N1/N2	3/28/22	5/8/36	0.030

The characteristics of age and clinical T/N staging were analyzed by independent-samples t-test. The data of gender and tumor markers of AFP/CEA/CA19-9 were analyzed by Pearson χ². A P < 0.05 was viewed as statistically significant. Non-DR: Disease non-response group; DR: Disease response group; SD: Standard deviation; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen.

Table 2 The area under the curve of radiomics model of DWI sequence, radiomics model of T2WI sequence, and radiomics model of portal phase of contrast-enhanced sequences models in the training set and the validation set

Sequence	Training set	P value	Validation set	P value
Ra-DWI	0.652 (95%CI, 0.571-0.726)	0.001	0.661 (95%CI, 0.536-0.772)	0.018
Ra-T2WI	0.628 (95%CI, 0.547-0.704)	0.005	0.575 (95%CI, 0.450-0.695)	0.291
Ra-CEPP	0.633 (95%CI, 0.552-0.709)	0.003	0.543 (95%CI, 0.418-0.664)	0.544

A P < 0.05 of the DeLong test was considered statistically significant. The DeLong test of validation set in radiomics model of T2WI sequence and radiomics model of portal phase of contrast-enhanced sequences had no statistical significance. Ra-DWI: Radiomics model of DWI sequence; Ra-T2WI: Radiomics model of T2WI sequence; Ra-CE_PP: Radiomics model of portal phase of contrast-enhanced sequences; CI: Confidence interval.